Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 4/20 | 0.64 |
| ▸ | G6PD | P11413 | 4/20 | 0.44 |
| ▸ | M6PR | P20645 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21711050 | 1.00 | IGF2R (0.64) | IGF2RG6PDM6PRCA1CA2 | |
| SCHEMBL1786879 | 1.00 | IGF2R (0.64) | IGF2RG6PDM6PRCA1CA2 | |
| SCHEMBL29323828 | 0.89 | IGF2R (0.51) | IGF2RG6PDM6PRCA1CA2 | |
| SCHEMBL2609683 | 0.84 | IGF2R (0.74) | IGF2RCA1CA2CA9P2RY2 | |
| SCHEMBL23743570 | 0.84 | IGF2R (0.69) | IGF2RCA1CA2CA9P2RY2 | |
| SCHEMBL10291466 | 0.83 | IGF2R (0.46) | IGF2RG6PDM6PRCA1CA2 | |
| SCHEMBL25494488 | 0.83 | IGF2R (0.59) | IGF2RCA1CA2CA9P2RY2 | |
| SCHEMBL25495348 | 0.83 | IGF2R (0.59) | IGF2RCA1CA2CA9P2RY2 | |
| SCHEMBL26951662 | 0.83 | IGF2R (0.59) | IGF2RP2RY2 | |
| SCHEMBL2609674 | 0.81 | IGF2R (0.74) | IGF2RCA1CA2CA9P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | IGF2R 3/4885G6PD 400/4885M6PR 1/4885 |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | IGF2R 185/4885G6PD 3160/4885M6PR 102/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | IGF2R 126/4885G6PD 2633/4885M6PR 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.